{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:58Z","timestamp":1792511518408,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anti-CD19-targeted chimeric antigen receptor (CAR) T cell therapy is effective in treating relapsed\/refractory diffuse large B-cell lymphoma (DLBCL). This therapy is associated with several side effects that can be life-threatening such as cytokine release syndrome (CRS). However, chylothorax associated with CRS after CAR-T therapy has not been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 23-year-old male diagnosed with DLBCL relapsing after autologous peripheral blood stem cell transplantation was treated with anti-CD19-targeted CAR-T cell therapy. After CAR-T cell transfusion, he developed grade 3 CRS includes fever, dyspnea, tachycardia and hypotension. The symptoms of CRS persisted and chest plain film revealed bilateral pleural effusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Chylothorax was confirmed by the pleural effusion analysis that triglyceride level was 1061\u2009mg\/dL. Bacterial and fungal culture of pleural fluid reported no pathogen was detected. Cytological examination of pleural effusion revealed no malignant cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The chylothorax resolved after treatment with intravenous administration of tocilizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>On 30-day follow-up, the patient was in stable clinical condition with complete remission of DLBCL on whole-body positron emission tomography scan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We reported a rare case of CAR-T associated chylothorax in a patient with relapsed and refractory DLBCL. Grade 3 CRS with high interleukin-6 level was presented in our patient. The symptoms of CRS were improved with tocilizumab treatment and the chylothorax resolved later on. It is suggested that high interleukin-6 releases might induce chyle leakage resulting from activations of endothelium and coagulation. Our finding highlights the occurrence of chylothorax during the course of CAR-T cell therapy and the importance of proper monitoring and prompt management of this life-threatening side effect.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035432","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:08:40Z","timestamp":1697231320000},"page":"e35432","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4602-5508","authenticated-orcid":false,"given":"Hsin-Hui","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yi","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department and Graduate Institute of Biology and Anatomy, National Defense Medical Center, Taipei City, Taiwan"},{"name":"UWELL Biopharma Inc., New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies.","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-cell lymphoma - Who, When, and How?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T Cell therapy: mechanism, management, and mitigation of inflammatory toxicities.","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia.","volume":"22","author":"Martino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials.","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.","volume":"5","author":"Wei","year":"2020","journal-title":"Sign Transduct Target Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"814548","DOI":"10.3389\/fimmu.2022.814548","article-title":"Correlation of cytokine release syndrome with prognosis after chimeric antigen receptor T cell therapy: analysis of 54 patients with relapsed or refractory multiple myeloma.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Disc"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia.","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Disc"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4049\/jimmunol.170.1.503","article-title":"Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression.","volume":"170","author":"Riedemann","year":"2003","journal-title":"J Immunol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10456-013-9393-2","article-title":"The effects of inflammatory cytokines on lymphatic endothelial barrier function.","volume":"17","author":"Cromer","year":"2014","journal-title":"Angiogenesis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2009.08.010","article-title":"Chylothorax: aetiology, diagnosis and therapeutic options.","volume":"104","author":"McGrath","year":"2010","journal-title":"Respir Med"},{"key":"R21-20250504","first-page":"e761","article-title":"Spontaneous resolution of chylothorax-associated lymphoma treated with external beam radiotherapy: a case report and comprehensive review of the literature.","volume":"8","author":"Joanna","year":"2016","journal-title":"Cureus"},{"key":"R22-20250504","first-page":"101662","article-title":"Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia.","volume":"37","author":"Makimoto","year":"2022","journal-title":"Resp Med Case Rep"},{"key":"R23-20250504","first-page":"71","article-title":"Dasatinib-induced chylothorax in chronic myeloid leukemia.","volume":"30","author":"Baloch","year":"2017","journal-title":"Proceedings"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:15:02Z","timestamp":1746324902000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035432","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}